Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has provided an announcement.
Lepu Biopharma Co., Ltd. has received marketing approval in China for its innovative drug MEIYOUHENG (Becotatug Vedotin Injection), the first EGFR-targeted ADC approved for recurrent or metastatic nasopharyngeal cancer (R/M NPC). This approval marks a significant milestone, enhancing treatment options for patients and potentially expanding the drug’s commercial value. The drug has shown clinically meaningful efficacy and a manageable safety profile, with promising results in combination therapy trials, indicating a strong potential impact on the company’s market positioning and stakeholder interests.
The most recent analyst rating on (HK:2157) stock is a Sell with a HK$6.00 price target. To see the full list of analyst forecasts on Lepu Biopharma Co. Ltd. Class H stock, see the HK:2157 Stock Forecast page.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a pharmaceutical company based in the People’s Republic of China, focusing on the development of innovative antibody drug conjugates (ADCs) for cancer treatment. The company targets the epidermal growth factor receptor (EGFR) to address various malignant solid tumors, including nasopharyngeal cancer.
Average Trading Volume: 21,606,796
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.47B
See more data about 2157 stock on TipRanks’ Stock Analysis page.